[Clinical significance of tumor content of epidermal growth factor receptor in breast cancer].
OBJECTIVE
To determine the content of epidermal growth factor receptor (EGFR) using a radioligand method in breast cancer and to analyze the relationship between the EGFR levels and the characteristics of patients and tumors. Prognostic significance was also analyzed.


METHODS
EGFR was measured by a single point radioligand assay in 265 invasive breast carcinomas tissues. In addition, estrogen and progesterone receptors (ER and PR) were measured by enzymatic immunoassays. We analyze the relationship of EGFR levels with the different clinico-pathologic parameters.


RESULTS
EGFR levels in breast carcinomas varied widely (0.1 to 403) with a median at 4 fmol/mg prot. The significantly higher concentrations of EGFR were detected in patients under 60 years old (p = 0.042), undifferentiated tumors (p = 0.04), and carcinomas with negative ER and PR (p < 0.019 y p < 0018, respectively). In addition, there was a negative correlation between EGFR and the ER and PR levels (p < 0.05). EGFR levels did not show any relationship with the patient's prognosis.


CONCLUSIONS
In addition, intratumoral levels of EGFR in breast carcinomas vary widely and the highest concentrations are associated with the most aggresive characteristics of the tumor.
Mulero
M
M
Medicina de Familia y Comunitaria del Hospital Central de Asturias. Oviedo. Asturias. Spain.
Fernández Raigoso
P
P
Vázquez
J
J
Lamelas
M L
ML
Corte
D
D
Allende
M T
MT
Rodríguez
J C
JC
Vizoso
F
F
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D002277:Carcinoma / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D066246:ErbB Receptors / Q000032:analysis*; D005260:Female; D006801:Humans; D015993:Life Tables; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000032:analysis; D011379:Prognosis; D011869:Radioligand Assay; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D066246:ErbB Receptors